Gilead Sciences, Inc. $GILD Shares Bought by Avanza Fonder AB

Avanza Fonder AB grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 130,929 shares of the biopharmaceutical company’s stock after purchasing an additional 3,890 shares during the quarter. Avanza Fonder AB’s holdings in Gilead Sciences were worth $16,070,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the 2nd quarter valued at about $30,000. MTM Investment Management LLC increased its position in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares in the last quarter. Kilter Group LLC purchased a new stake in Gilead Sciences in the second quarter valued at about $33,000. Finally, Board of the Pension Protection Fund purchased a new stake in Gilead Sciences in the fourth quarter valued at about $37,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition adds OM336 (gamgertamig), a BCMAxCD3 T‑cell engager designed for rapid, deep B‑cell depletion—strengthens Gilead’s inflammation/autoimmune pipeline and provides a near‑term clinical asset that could drive future revenue if successful. Gilead Sciences to Acquire Ouro Medicines (Business Wire)
• Positive Sentiment: Major media and wire coverage confirms deal size and strategic rationale, increasing market confidence around the transaction’s credibility and near‑term impact. Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion (WSJ) Gilead to buy biotech firm Ouro Medicines in over $2 billion deal (Reuters)
• Positive Sentiment: Analyst support: Bank of America maintained a Buy rating and $162 price target, citing HIV franchise momentum and product upside—analyst backing can bolster investor sentiment. Buy Rating on Gilead (TipRanks / BofA)
• Neutral Sentiment: Health care sector strength is supporting stocks broadly, providing incidental tailwinds to GILD alongside the M&A news. Gilead nears up to $2bn deal for autoimmune biotech (Yahoo Finance)
• Neutral Sentiment: Reported March short‑interest data appear anomalous (showing zero/share changes and NaN), suggesting no clear short‑position signal from the data release. No reliable market pressure evident from short interest.
• Negative Sentiment: Deal and clinical risk: the price (up to $2.18B) is material and the asset is clinical‑stage—clinical trial failure, integration costs, or disappointments on OM336’s commercial potential could weigh on the stock. Gilead nearing up to $2 billion buyout of Ouro Medicines (Reuters)

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. The trade was a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 309,280 shares of company stock valued at $44,068,850. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. TD Cowen increased their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Wolfe Research boosted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Price Performance

Shares of GILD opened at $137.34 on Tuesday. The business’s 50-day moving average is $142.98 and its two-hundred day moving average is $128.15. The company has a market capitalization of $170.50 billion, a P/E ratio of 20.29, a P/E/G ratio of 1.80 and a beta of 0.36. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the business earned $1.90 earnings per share. The company’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.